Inicio / De Interés / Artículos Científicos / Epidemiology of Adverse Cutaneous Drug Reactions. A Prospective

Epidemiology of Adverse Cutaneous Drug Reactions. A Prospective

Study in Hospitalized Patients

Amparo Herna´ndez-Salazar,a Samuel Ponce-de-Leo´n Rosales,b Sigfrido Rangel-Frausto,b
Elia Criollo,c Carla Archer-Dubon,a and Roc?´o Orozco-Topetea
aDermatology Department, bSubdivision of Hospital Epidemiology and Patient Care Quality Control, cPharmacy Department,
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubira´n, Mexico City, Mexico
Received for publication June 2, 2005; accepted March 20, 2006 (ARCMED-D-05-00211).

Background. Drug reactions are commonly present in the skin; however, their frequency
in our setting is unknown.

Methods. A 10-month prospective cohort study including all hospitalized patients was
designed. Those with adverse cutaneous drug reactions (ACDR) were clinically identified.

Results. Thirty five drug reactions (prevalence of 0.7%) were seen among 4785 (2713 females,
2072 males) discharged patients. According to Begaud’s imputability criteria, the
reactions were most likely attributed to a drug in 4.87%, likely in 41.46% and possible in
53.65%. The most commonly seen dermatoses were morbilliform rash 51.2%, urticaria
12.2% and erythema multiforme 4.9%. Drugs most frequently associated with ACDR
were amoxicillin clavulanate (8), amphotericin B (2) and metamizole (4). Expressed as
risk by 1000 day-doses (Dd: the risk a patient has of developing an ACDR after receiving
1 day of treatment with the drug): amoxicillin clavulanate Dd 7.7, amphotericin B Dd 4.8
and metamizole Dd 3.7. Immunosuppressed patients were most frequently affected. Notably,
patients with systemic lupus erythematosus (SLE) had a 4.68 higher risk (CI 95%
1.794e12.186 p !0.001) of developing an ACDR. AIDS patients showed a risk of 8.68
(CI 95% 2.18e33.19 p !0.001). Non-Hodgkin’s lymphoma patients also had an increased
risk of developing an ACDR. Six of the 35 identified cases were patients who
had been hospitalized due to a severe drug reaction (1.3/1000 patients); one died from
complications directly related to the ACDR, representing a 16.6% mortality rate among
those admitted for an ACDR and 0.02% among the global mortality.

Conclusions. We have a low prevalence of drug reactions compared to data reported in
the literature. Pharmacovigilance with special attention to immunosuppressed SLE or
AIDS patients is stressed. _ 2006 IMSS. Published by Elsevier Inc.

Acerca de PIEL-L

Mesa de redacción de Piel Latinoamericana. Donde recibimos casos, aportes e información de interés para la comunidad latinoamericana dermatólogica

Deja un comentario

Para casos clínicos, sólo se publicarán comentarios de Suscriptores Especialistas de Salud registrados en nuestra base de datos.

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

 

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies